The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D(2) receptor antagonism and fast receptor dissociation properties

European Journal of Pharmacology
Tino DyhringNicholas Waters

Abstract

A new pharmacological class of CNS ligands with the unique ability to stimulate or suppress motor and behavioral symptoms depending on the prevailing dopaminergic tone has been suggested as "dopaminergic stabilizers". The molecular mode-of-action of dopaminergic stabilizers is not yet fully understood, but they are assumed to act via normalization of dopaminergic signaling, through interactions with the dopamine D(2) receptor. Here we have evaluated the dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162, as well as the new compound N-{[(2S)-5-chloro-7-(methylsulfonyl)-2,3-dihydro-1,4-benzodioxin-2-yl]methyl}ethanamine (NS30678) in a series of cellular in vitro dopamine D(2) receptor functional and binding assays. Neither ACR16, (-)-OSU6162, nor NS30678 displayed detectable dopamine D(2) receptor-mediated intrinsic activity, whereas they concentration-dependently antagonized dopamine-induced responses with IC(50) values of 12.9microM, 5.8microM, and 7.0nM, respectively. In contrast to the high-affinity typical antipsychotics haloperidol and raclopride, the dopaminergic stabilizers ACR16 and (-)-OSU6162 both displayed fast dopamine D(2) receptor dissociation properties, a feature that has previously been suggested as a ...Continue Reading

References

Feb 26, 2000·European Journal of Pharmacology·A EkesboJ Tedroff
Jul 8, 2000·Proceedings of the National Academy of Sciences of the United States of America·A Abi-DarghamM Laruelle
Jun 14, 2002·European Journal of Pharmacology·Shaun JordanC Anthony Altar
Jun 18, 2002·The Journal of Pharmacology and Experimental Therapeutics·Kevin D BurrisPerry B Molinoff
Feb 18, 2004·Current Medicinal Chemistry·M L CarlssonM Nilsson
May 26, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Johan P RungMaria L Carlsson
Oct 24, 2006·European Journal of Pharmacology·Julia N HeinrichTerrance H Andree
Dec 13, 2006·European Journal of Pharmacology·Philip Seeman, Hong-Chang Guan
Jun 30, 2007·Annual Review of Neuroscience·Wolfram Schultz
Aug 16, 2008·Journal of Psychopharmacology·Peter Fitzgerald, Timothy G Dinan
Mar 10, 2009·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Faïza BenaliouadPierre-Paul Rompré

❮ Previous
Next ❯

Citations

May 3, 2011·Naunyn-Schmiedeberg's Archives of Pharmacology·Johan P RungMaria L Carlsson
Feb 15, 2012·Naunyn-Schmiedeberg's Archives of Pharmacology·Georges VauquelinPhilip Seeman
Mar 9, 2012·European Journal of Clinical Pharmacology·A HelldénL Bertilsson
Aug 30, 2011·Journal of Neural Transmission·Maria L CarlssonArvid Carlsson
May 19, 2011·Clinical Neuropharmacology·Mouna EsmaeilzadehJoakim Tedroff
Oct 19, 2011·Future Medicinal Chemistry·Seetharama D Satyanarayanajois, Ronald A Hill
Sep 25, 2014·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Nelleke TolboomArvid Carlsson
Jan 8, 2014·European Journal of Medicinal Chemistry·Cecilia MattssonClas Sonesson
May 13, 2014·Journal of Neural Transmission·Susanna WatersNicholas Waters
Feb 18, 2016·Expert Opinion on Investigational Drugs·Kathleen M Shannon
Oct 1, 2013·The International Journal of Neuropsychopharmacology·Kristoffer SahlholmPeter Århem
Jan 13, 2015·Parkinsonism & Related Disorders·Daniel ZielonkaG Bernhard Landwehrmeyer
Jan 27, 2016·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Kristoffer SahlholmPeter Århem
Dec 22, 2016·ACS Chemical Neuroscience·Ramin Ekhteiari SalmasSerdar Durdagi
Jul 29, 2016·Human Molecular Genetics·Michal GevaMichael R Hayden
May 9, 2018·Movement Disorders : Official Journal of the Movement Disorder Society·Karl KieburtzC Warren Olanow
Nov 28, 2017·Bulletin of Experimental Biology and Medicine·A V Bol'shakovaI B Bezprozvanny
Sep 22, 2018·Nature Reviews. Drug Discovery·Nicholas S CaronMichael R Hayden
Jul 16, 2019·Journal of Neuroscience Research·Ellen T Koch, Lynn A Raymond
Feb 23, 2020·Reviews in the Neurosciences·Magdalena JabłońskaPrzemysław Gałązka
Jul 13, 2013·Movement Disorders : Official Journal of the Movement Disorder Society·Ralf Reilmann
Oct 17, 2014·Expert Review of Clinical Pharmacology·Anne-Catherine Vijverman, Susan H Fox
Dec 19, 2016·Drugs·Emma M Coppen, Raymund A C Roos
Feb 14, 2019·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Veronica FrancardoM Angela Cenci
May 17, 2019·Journal of Neurochemistry·Amy I Smith-DijakLynn A Raymond
Sep 26, 2019·Frontiers in Neuroscience·Daniel A RyskampIlya Bezprozvanny
Feb 27, 2018·Journal of Huntington's Disease·Susanna WatersNicholas Waters
Apr 20, 2021·Journal of Neurochemistry·Marina ShenkmanGerardo Z Lederkremer
Jul 27, 2021·Frontiers in Physiology·Richa AishwaryaMd Shenuarin Bhuiyan
Jul 30, 2010·European Journal of Pharmacology·Henrik PontenNicholas Waters

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Calcium & Bioenergetics

Bioenergetic processes, including cellular respiration and photosynthesis, concern the transformation of energy by cells. Here is the latest research on the role of calcium in bioenergetics.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here